Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BACKGROUND AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life OBJECTIVE AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life METHODS MATERIAL & METHODS:This is a Two year prospective study from August 2013 to August 2015.Patients with a proven malignancy with bone scan positive metastatic skeletal lesions were taken and the clinical, biochemical & radiological manifestations of were analysed.Pain score by visual analogue score (VAS) both pre-treatment and post treatment were noted. Quality of life was noted at the baseline using European Organization for Research and Treatment of Cancer Quality of Life Group (EORTC) -Q30 questionnaire. RESULTS It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment. CONCLUSIONS It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment.
BACKGROUND AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life OBJECTIVE AIM:To study the clinical, biochemical , radioligical profile of bone metastases along with distribution of skeletal metastases with management strategies and effect on quality of life METHODS MATERIAL & METHODS:This is a Two year prospective study from August 2013 to August 2015.Patients with a proven malignancy with bone scan positive metastatic skeletal lesions were taken and the clinical, biochemical & radiological manifestations of were analysed.Pain score by visual analogue score (VAS) both pre-treatment and post treatment were noted. Quality of life was noted at the baseline using European Organization for Research and Treatment of Cancer Quality of Life Group (EORTC) -Q30 questionnaire. RESULTS It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment. CONCLUSIONS It was observed that majority of patients were males (58.8%).Bone metastases was most common in lung malignancy (30.4%) followed by carcinoma prostate (19.2%). Carcinoma breast was the third most common malignancy (18.8%) and most common malignancy with bone metastases in females. Pain was the most common presentation (83.6%).Alkaline phosphatase was raised in 80 % of cases & lactate Dehydrogenase was high in 92.4%.Osteolytic lesions were seen in 56.4% cases, osteosclerotic/osteoblastic in 32.4% while 11.2% cases had mixed lesions. Target X-ray imaging was positive in 46.8%, computed tomography (CT) scan 86.6%,magnetic resonance imaging (MRI) 81.4%,positron emission tomography (PET/CT) scan 93.3%. Non-Opiod analgesics were commonly used in 83.2% cases followed by Bisphosphonates in 82% .Pain score as per VAS scale improved significantly in all cases of bone metastases post intervention.Quality of life as per EORTC-30 questionnaire was impaired significantly in all cases with 86% cases having moderate to severe impairment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.